Skip to content

To evaluate the efficacy of the investigational product, Cognitus/Bacomind, in comparison to placebo, in the treatment of ADHD disorder in children and adolescents

Efficacy & safety of a standardized extract from Bacopa monnieri in children & adolescents with attention deficit hyperactivity disorder (ADHD): A Randomized, Double-blind, Placebo-controlled with an extended open label clinical trial. - NA

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/080248
Enrollment
136
Registered
2025-02-10
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F900- Attention-deficit hyperactivity disorder, predominantly inattentive type

Interventions

None listed

Sponsors

Natural Remedies
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children or adolescents of both sexes between 6 and 16 years old both inclusive who exhibit mild to moderate ADHD with predominantly inattentive or combined presentation according to DSM V criteria assessed via the MINI KID Inattentive subset and hyperactivity subset of not greater than 22 on SNAP IV scale Voluntary Assent to participate in the study from all those who are more than 7 years of age Informed Consent Form signed by legal guardians research participant when possible Results of laboratory tests chemistry blood count and urine physical examination and vital parameters with no clinically significant changes clinically significant changes are defined as laboratory results requiring acute drug intervention indicating severe illness or requiring further medical evaluation according to the discretion of the investigator

Exclusion criteria

Exclusion criteria: Wechsler Intelligence Scale for Children Fourth Edition Short Form WISC IV SF score subjects whose scores are less than 80 To be administered by a psychiatrist or a clinical psychologist Patients diagnosed with previous cognitive development delay Research participants with known hypersensitivity to the other medications History of alcohol or drug abuse by the research participant Where the immediate concern is around another Primary psychiatric diagnoses other than ADHD Diagnosis of psychiatric comorbidities except for simple phobia adjustment disorders learning disorders oppositional defiant disorder sleep disorders mild anxiety and or mild depressions History of seizures except for mild febrile seizures within 2 years from the time of recruitment Diagnosis of Tourette Syndrome and chronic tics Research participants who are making use of drugs for the treatment of ADHD in the last three months Research participants who are making use of anticonvulsants antidepressants and antipsychotics up to 6 weeks prior to study entry or during the same Positive beta HCG test for girls who have attained menarche Patients at identified risk of suicide through clinical interview Children or adolescents with ADHD predominantly hyperactive or impulsive Other conditions considered by the investigator as reasonable for disqualification of the subjects participation in the study

Design outcomes

Primary

MeasureTime frame
ADHD symptoms as measured by the SNAP IV CGI I Scale scoresTimepoint: Timeframe on week 0 6 14 and 28 Timeframe on week 0 6 14 and 28

Secondary

MeasureTime frame
Computer based Continuous Performance Test scores Rey Auditory Verbal Learning Test RAVLT scoresTimepoint: Timeframe on week 0 14 & 28 Timeframe on week 0 14 & 28

Countries

India

Contacts

Public ContactArabinda Patnaik

Syncorp Health Pvt. Ltd.

arvind.p@syncorphealth.com9014308214

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026